This Article Full Text Full Text (PDF) Online Data Supplement Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sharma, S. K. Articles by Mehra, N. K. Search for Related Content PubMed PubMed Citation Articles by Sharma, S. K. Articles by Mehra, N. K.

Evaluation of Clinical and Immunogenetic Risk Factors for the Development of Hepatotoxicity during Antituberculosis Treatment

Departments of Medicine, Histocompatibility and Immunogenetics, and Biostatistics, All India Institute of Medical Sciences, New Delhi, India

Correspondence and requests for reprints should be addressed to S. K Sharma, Professor, Department of Medicine, All India Institute of Medical Sciences, New Delhi-110029, India. E-mail: surensk{at}hotmail.com

Though several risk factors for the development of hepatotoxicity due to antituberculosis drugs have been suggested, involvement of genetic factors is not fully established. We have studied the major histocompatibility complex (MHC) class II alleles and clinical risk factors for the development of hepatotoxicity in 346 North Indian patients with tuberculosis undergoing antituberculosis treatment. Of these, 56 patients developed drug-induced hepatotoxicity (DIH group), whereas the remaining 290 patients did not (non-DIH group). The DIH group was comparatively older, had lower pretreatment serum albumin, and a higher frequency of moderately/far advanced disease radiographically than the latter. Further, patients with high alcohol intake had threefold higher odds of developing hepatotoxicity. In multivariate logistic regression analysis, older age (odds ratio [OR] 1.2), moderately/far advanced disease (OR 2.0), serum albumin < 3.5 g/dl (OR 2.3), absence of HLA-DQA1*0102 (OR 4.0), and presence of HLA-DQB1*0201 (OR 1.9) were independent risk factors for DIH. Our results suggest that the risk of hepatotoxicity from antituberculosis drugs is influenced by clinical and genetic factors.

Key Words: antituberculosis drugs • hepatotoxicity • human leukocyte antigens

This article has been cited by other articles:

				Y. S. Kwon, W.-J. Koh, G. Y. Suh, M. P. Chung, H. Kim, and O. J. Kwon Hepatitis C Virus Infection and Hepatotoxicity During Antituberculosis Chemotherapy Chest, March 1, 2007; 131(3): 803 - 808. [Abstract] [Full Text] [PDF]

				J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]

				D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, and D. Menzies Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1472 - 1477. [Abstract] [Full Text] [PDF]

				M. J. Tobin Tuberculosis, Lung Infections, Interstitial Lung Disease, and Journalology in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 345 - 355. [Full Text] [PDF]

				G. H. Bothamley Treatment, Tuberculosis, and Human Leukocyte Antigen Am. J. Respir. Crit. Care Med., October 1, 2002; 166(7): 907 - 908. [Full Text]